Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

Oral mucositis induced by anticancer treatments: physiopathology and treatments

Authors D’Hondt, Lionel, Lonchay, Christophe, André, Marc, Canon, Jean-Luc

Published 15 June 2006 Volume 2006:2(2) Pages 159—168

D’Hondt, Lionel, Lonchay, Christophe, André, Marc, Canon, Jean-Luc

 

Centre Hospitalier Notre-Dame et Reine Fabiola, Charleroi, Belgium

 

Abstract: Oral mucositis is a frequent and devastating side effect of anticancer treatments. It impairs the patient’s quality of life and also can be life threatening because severe infections and delayed or incomplete anticancer treatments may result. This problem has been largely overlooked and underestimated in the past. However, recently studies have been performed to precisely identify the epidemiology, cost, consequences, physiopathology, and treatments of oral mucositis. Clinical guidelines have recently been published to help the daily management of this frequent complication. In addition, some innovative new drugs, including palifermin, have been developed to prevent and treat this major side effect of cancer treatments. In this paper we summarize the recent developments of oral mucositis management.

 

Keywords: chemotherapy, radiotherapy, oral mucositis, palifermin

Download Article [PDF] 

Readers of this article also read:

Effects of treatment with antimicrobial agents on the human colonic microflora

Fatemeh Rafii, John B Sutherland, Carl E Cerniglia

Therapeutics and Clinical Risk Management 2008, 4:1343-1357

Published Date: 5 December 2008

Acute migraine: Current treatment and emerging therapies

Arun A Kalra, Debra Elliott

Therapeutics and Clinical Risk Management 2007, 3:449-459

Published Date: 15 July 2007

Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model

Carin A Uyl-de Groot, Joseph McDonnell, Guul ten Velde, David Radice, Harry J M Groen

Therapeutics and Clinical Risk Management 2006, 2:317-323

Published Date: 15 September 2006

Editorial ||FREE PAPER||

Garry Walsh

Therapeutics and Clinical Risk Management 2006, 2:227-228

Published Date: 15 September 2006

Treatment of pruritic diseases with topical calcineurin inhibitors

Sonja Ständer, Funda Schürmeyer-Horst, Thomas A Luger, Elke Weisshaar

Therapeutics and Clinical Risk Management 2006, 2:213-218

Published Date: 15 June 2006